Léčba risankizumabem u pacienta s anamnézou infekčních onemocnění
| Title in English | Risankizumab treatment of patient with history of infectious diseases |
|---|---|
| Authors | |
| Year of publication | 2021 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that binds with high affinity to the p19 subunit and selectively inhibits interleukin 23 (IL-23). Inhibition of IL- 23 causes selective blockade of differentiation of the pathogenic Th 17 lymphocytes only. During risankizumab treatment the levels of interleukin 17 remain physiological which contributes to maintaining normal skin and mucosa barrier fuction. The case report presents progress of disease and treatment of male patient with severe psoriasis who suffered from recurring streptococcal infections. |